Positives

• Dipyridamole surfaces in Long COVID discussions because its adenosine-reuptake-inhibitor mechanism is relevant to fatigue biology, and microclot hypotheses have generated interest in antiplatelet drugs beyond the usual aspirin-clopidogrel-DOAC triple FDA.

Negatives

• Dipyridamole's most prominent adverse effect is headache, and intravenous infusions triggered headache in all migraine patients and 8 of 10 healthy controls in one provocation study PubMed.
• For Long COVID and ME/CFS patients, headache or migraine already affects 40 to 80% of patients, so adding a known headache provoker risks worsening the symptom most cited as severe PMC.
• Common discontinuation reasons include flushing, dizziness, and orthostatic hypotension on top of headache Cleveland Clinic.

Hurdles & Side Effects

• Dipyridamole is prescription-only and its approved indication is secondary stroke prevention — using it for Long COVID is off-label FDA.
• The FDA prescribing information lists headache as the most common adverse reaction, often in the first week. It is also a vasodilator, so patients with POTS or baseline hypotension should monitor for drops in blood pressure FDA.
• If you are already on the Pretorius-style triple-anticoagulation protocol (aspirin + clopidogrel + DOAC), adding dipyridamole layers on additional bleeding risk — this is a conversation for your clinician, not a do-it-yourself decision FDA.